Boehringer Ingelheim Pharmaceuticals, Inc.

182 articles with Boehringer Ingelheim Pharmaceuticals, Inc.

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Study Published in The New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis

  9/22/2011

• Boehringer Ingelheim Pharmaceuticals, Inc. to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves

  8/26/2011

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: TV Star Susan Lucci Takes Message of Reducing Atrial Fibrillation-Related Stroke Risk to The Airwaves Through Personal Story and Pledge

  8/3/2011

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: Pradaxa® (dabigatran etexilate mesylate) Capsules Now on Formulary at Nation's Top Heart Hospitals

  7/21/2011

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: Two-Year Data Comparing Cardiovascular Events with Linagliptin and the Sulfonylurea, Glimepiride, Presented as Late-Breaking Poster at American Diabetes Association

  6/27/2011

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Phase III Data and Pooled Analysis for Linagliptin Show Improved Blood Sugar Control in Adults With Type 2 Diabetes When Used Alone and With Metformin

  6/27/2011

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: Linagliptin Recommended for Approval in the Treatment of Type 2 Diabetes in Europe

  6/24/2011

• Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company to Feature Type 2 Diabetes Research in More Than 25 Presentations at the 71st American Diabetes Association Scientific Sessions

  6/20/2011

• Unity Management Group, MCC Receives Purchase Order From Boehringer Ingelheim Pharmaceuticals, Inc.

  6/16/2011

• Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company's New Type 2 Diabetes Treatment Tradjenta™ (Linagliptin) Tablets for Adults Now Available in U.S. Pharmacies

  6/15/2011

• Boehringer Ingelheim Pharmaceuticals, Inc.'s Pradaxa(R) (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP(R), Nation's Largest Provider of Medicare Part D Coverage

  5/19/2011

• New Subanalyses of the RE-LY Trial Showed Boehringer Ingelheim Pharmaceuticals, Inc.'s Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation

  4/4/2011

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion

  1/5/2011

• FDA Approves Boehringer Ingelheim Pharmaceuticals, Inc.'s Pradaxa to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation

  10/20/2010

• U.S. Panel Backs Boehringer Ingelheim Pharmaceuticals, Inc. Drug Dabigatran Etexilate to Reduce Strokes

  9/22/2010

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: Dabigatran Etexilate as Effective and Safe as Enoxaparin in Preventing Venous Thromboembolism (VTE) After Total Hip Replacement Surgery and Significantly Reduced the Combined Endpoint of Major VTE and VT

  6/11/2010

• Boehringer Ingelheim Vetmedica, Inc. (JOBS) May Add 50 New Jobs

  9/23/2009

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed

  7/20/2009

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Data on Once-Daily Extended Release Pramipexole Presented at 13th International Congress of Parkinson’s Disease and Movement Disorders (MDS)

  6/10/2009

• Boehringer Ingelheim Pharmaceuticals, Inc. New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting

  4/29/2009